1 2Q 2019 Earnings August 6, 2019 Building a Premier Women's Health Portfolio TherapeuticsMD® For Her. For Life. Forward-Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to ___________ Commission File No. 001-00100 FL (Address of Principal Executive Offices) (Zip Code) (561) 961-1900 (Registrant's Telephone Number, includ ...

Financial Data and Key Metrics Changes - In Q1 2019, approximately 75,000 units of IMVEXXY were dispensed, a significant increase from approximately 47,500 units in Q4 2018 [43] - Net revenue for IMVEXXY was approximately $2 million for Q1 2019, representing a 122% increase over Q4 2018 [45] - The net loss for Q1 2019 was approximately $39.5 million, compared to a net loss of approximately $24.4 million in Q1 2018 [50] Business Line Data and Key Metrics Changes - IMVEXXY achieved a 6% market share within 10 months of launch, with an average of over three fills per patient [11][12] - Net revenue from the prescription prenatal vitamin business was approximately $1.9 million for Q1 2019, down from approximately $3.8 million in Q1 2018 [47] Market Data and Key Metrics Changes - The patient mix for IMVEXXY is over-weighted towards Medicare Part D, which currently has the lowest coverage and utilization [16] - The overall blended adjudication rate for IMVEXXY was 27% in Q1 2019, with a 41% adjudication rate for commercial plans and a 5% rate for Medicare Part D [18] Company Strategy and Development Direction - The company aims to achieve a normalized net revenue goal of $108 per unit for IMVEXXY by Q3 2020, heavily weighted towards maintenance packs [14] - The launch strategy for BIJUVA will mirror that of IMVEXXY, focusing on prescriber education and building payer coverage [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving higher net revenue as payer coverage increases, with expectations of 70% commercial payer coverage by Q3 2019 [14][45] - The company anticipates that the majority of the gap between current revenue and the target of $108 per unit will close by the end of 2019 [20] Other Important Information - The company entered into a $300 million non-dilutive term loan facility with TPG Sixth Street Partners, with initial funding of $200 million [51] - The company views ANNOVERA as a potential game changer in the contraceptive market, with a planned soft launch in Q3 2019 [35][38] Q&A Session Summary Question: Can you outline the covenants for your new debt piece? - The most important covenant allows for an additional $15 million if $11 million in revenue from all three products is reached in Q4 [62] Question: What is the current growth to net for IMVEXXY? - The target is $108 per unit, with expectations that the majority of the gap will close this year as payer contracting is completed [63] Question: Do you owe any royalties on your products? - Currently, there are no royalties, but royalties will apply to ANNOVERA once it starts selling [64] Question: Is the vitamins business a core asset? - The vitamins business serves as a feeder for ANNOVERA, connecting with new patients who may transition to contraception later [65] Question: What has been surprising about IMVEXXY's launch? - The rapid volume growth has exceeded expectations, indicating strong adoption among prescribers and patients [74] Question: When will you report to IQVIA or other databases? - Symphony data is close to actual performance, and the company is working with IQVIA for more accurate reporting [72] Question: How does the copay assistance program work? - The copay assistance program is managed through RelayHealth and Truveris, allowing the company to maintain contact with patients for compliance and education [122]

| --- | --- | |-------|-------| | | | | | | | | | | | | 1 1 Q 1 9 T X M D U P D AT E Building a Premier Women's Health Portfolio TherapeuticsMD® For Her. For Life. Forward-Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than historical facts, that address activities, event ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Commission File Number 001-00100 (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) Nevada 87-0233535 (I.R.S. Employer Identification No.) 6800 Broken Sound Parkway NW, Third Floor Boca Raton, Florida 33487 (561) 961-1900 (Address, in ...